Italiano
Antiphospholipid Antibody Syndrome ( APLS ) is an autoimmune disease that may manifest venous and / or arterial thrombosis. It was studied since the end of the 20th century as a potential cause of thrombosis, recurrent abortion, blood and skin alterations. Today, syndrome is considered a more complex pathology, with different neurological, cardiac and vascular manifestations that may mimic other conditions, autoimmune and non-existent, may also occur during other diseases (secondary APLS) or may remain as a form of self (APLS Primary).
The diagnosis is based on laboratory alterations (presence of anti-cardiolipin antibodies, anticoagulant lupus, anti-beta2glicoprotein I or other antiphospholipids) and clinical manifestations. All of these elements, which were defined in detail during the Sapporo International Congress in 1998 and updated following the new evidence, may address a diagnosis of APLS.
Therapies are mainly based on the prevention of thrombotic recurrences, performed with anticoagulant or platelet antiaggregating drugs. In pregnancy and in the forms of less frequent APLS there are other medications available, in addition to those used as a result of clinical events.
| Ref. | Description | Package | |
| ELISA | |||
| 4098 | Anti-CARDIOLIPINAIgG | 96 tests | |
| Cardiolipin is an anionic phospholipid rich in the internal mitochondrial membrane against which IgM and IgM antibodies are directed, in the presence of an important cardiolipin cofactor, β2 glycoprotein I. In the APLS syndrome, recurrent venous and / or arterial thromboses, polygalactivity and presence of antiphospholipid antibody serum occur. It distinguishes a primary APS and a secondary APS to connect, in particular LES. Following extensive studies on individual antiphospholipids or a mixture of these, it has been demonstrated that a combination of phosphatidylserine, phosphoric acid and Beta2-Glycoprotein I allows a better distinction between sera of patients with antiphospholipid syndrome and patients with other disorders diseases, particularly syphilis. 100% sensitivity. Specificity & gt; 99%. Ready-to-use liquid reagents. Stable up to the expiration date.
Reaction at 37 ° C. After dispensing the pre-diluted sample, wait 60 minutes for the first incubation, wash the wells, enzyme conjugate dispensing, 30 minute incubation, well wash, and chromogen dispensing. After 10 minutes, block the reaction by dispensing the stop solution. Standard included in the kit. |
|||
| 4099 | Anti-CARDIOLIPINA IgM | 96 tests | |
| Cardiolipin is an anionic phospholipid rich in the internal mitochondrial membrane against which IgM and IgM antibodies are directed, in the presence of an important cardiolipin cofactor, β2 glycoprotein I. In the APLS syndrome, recurrent venous and / or arterial thromboses, polygalactivity and presence of antiphospholipid antibody serum occur. It distinguishes a primary APS and a secondary APS to connect, in particular LES. Following extensive studies on individual antiphospholipids or a mixture of these, it has been demonstrated that a combination of phosphatidylserine, phosphoric acid and Beta2-Glycoprotein I allows a better distinction between sera of patients with antiphospholipid syndrome and patients with other disorders diseases, particularly syphilis. 100% sensitivity. Specificity & gt; 99%. Ready-to-use liquid reagents. Stable up to the expiration date.
Reaction at 37 ° C. After dispensing the pre-diluted sample, wait 60 minutes for the first incubation, wash the wells, enzyme conjugate dispensing, 30 minute incubation, well wash, and chromogen dispensing. After 10 minutes, block the reaction by dispensing the stop solution. Standard included in the kit. |
|||
| LUPUS ANTICOAGULANTE LAC
METODO COAGULATIVO |
|||
| 217B | LUPUS anticoagulante (LAC) | 2×1+1×2.5 ml | |
| Anticoagulant Lupus (LA) belongs to the group of anti-phospholipid antibodies that are directed against negatively charged phospholipids or to phospholipid-protein complexes (eg b-2-glycoprotein or thrombin). In their presence there is an extension of dependent phospholipid tests such as APTT, Kaolin Clotting Time (KCT) or dRVVT (diluted Russel Viper Venom Time): patients with LA antibodies are at risk for clinical complications such as recurrent thrombosis and abortion. The kit uses dRVVT reagents and allows for a screening with subsequent confirmation for antibody LA search. The kit consists of three reagents, of which R1 and R2 are based on Russell’s venom poison, with the difference in the concentration of phospholipids present: in the R1, used for screening, the concentration is lower, so the sensitivity of the reagent; In R2, however, the concentration of phospholipids is higher and neutralizes the presence of Lupus Anticoagulant, shortening the reaction times. Russell’s viper poison in the presence of calcium ions (supplied in the kit as CaCl2 2 ) directly activates Factor X in the samples. Therefore, the LAC kit does not suffer interference due to anomalies of contact factors, Factors VII, VIII and IX deficiencies or the presence of inhibitors. The heparin interference is neutralized by the polybrane up to the concentration of 1 U / ml of heparin. The kit is therefore more specific than APTT methods.
Reaction at 37 ° C. Dispense 100 m of citrated plasma, 100 l of R1 LA screen and 100 em> m l of CaCl 2 . If results exceed 45 seconds, you need to reduce using the R2LA Confirm instead of R1 |
|||